{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:15:55Z","timestamp":1786979755861,"version":"build-2736575974"},"reference-count":121,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T00:00:00Z","timestamp":1734998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82474006"],"award-info":[{"award-number":["82474006"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical Toxicology Foundation of Chinese Society of Toxicology","award":["CST2020CT107"],"award-info":[{"award-number":["CST2020CT107"]}]},{"name":"Research Project of Drug Clinical Evaluation Professional Committee of China Pharmaceutical Association","award":["CPA-CDCER-2021-008"],"award-info":[{"award-number":["CPA-CDCER-2021-008"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Toxicol"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s00204-024-03950-9","type":"journal-article","created":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T10:58:43Z","timestamp":1735037923000},"page":"835-850","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Drug-induced hepatic sinusoidal obstruction syndrome: current advances and future perspectives"],"prefix":"10.1007","volume":"99","author":[{"given":"Zaoqin","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9429-4764","authenticated-orcid":false,"given":"Chengliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,24]]},"reference":[{"issue":"5","key":"3950_CR1","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41409-017-0066-4","volume":"53","author":"ME Abate","year":"2018","unstructured":"Abate ME, Paioli A, Cammelli S et al (2018) Sinusoidal obstruction syndrome\/veno-occlusive disease after high-dose intravenous busulfan\/melphalan conditioning therapy in high-risk Ewing sarcoma. Bone Marrow Transpl 53(5):591\u2013599. https:\/\/doi.org\/10.1038\/s41409-017-0066-4","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"3950_CR2","first-page":"1953","volume":"34","author":"Y Arakawa","year":"2014","unstructured":"Arakawa Y, Shimada M, Utsunomiya T et al (2014) Bevacizumab improves splenomegaly and decreases production of hyaluronic acid after L-OHP based chemotherapy. Anticancer Res 34(4):1953\u20131958","journal-title":"Anticancer Res"},{"issue":"10","key":"3950_CR3","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1200\/JCO.2004.08.075","volume":"22","author":"C Arndt","year":"2004","unstructured":"Arndt C, Hawkins D, Anderson JR et al (2004) Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide. J Clin Oncol 22(10):1894\u20131901. https:\/\/doi.org\/10.1200\/JCO.2004.08.075","journal-title":"J Clin Oncol"},{"key":"3950_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2019.08.009","volume":"20","author":"STA Barcelos","year":"2021","unstructured":"Barcelos STA, Dall\u2019Oglio VM, de Ara\u00fajo A, Cerski CTS, \u00c1lvares-da-Silva MR (2021) Sinusoidal obstruction syndrome secondary the intake of Senecio brasiliensis: a case report. Ann Hepatol 20:100138. https:\/\/doi.org\/10.1016\/j.aohep.2019.08.009","journal-title":"Ann Hepatol"},{"key":"3950_CR5","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.ejrad.2017.06.025","volume":"94","author":"S Cayet","year":"2017","unstructured":"Cayet S, Pasco J, Dujardin F et al (2017) Diagnostic performance of contrast-enhanced CT-scan in sinusoidal obstruction syndrome induced by chemotherapy of colorectal liver metastases: radio-pathological correlation. Eur J Radiol 94:180\u2013190. https:\/\/doi.org\/10.1016\/j.ejrad.2017.06.025","journal-title":"Eur J Radiol"},{"issue":"8","key":"3950_CR6","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1080\/08880010701640390","volume":"24","author":"E Cecen","year":"2007","unstructured":"Cecen E, Uysal KM, Ozguven A et al (2007) Veno-occlusive disease in a child with rhabdomyosarcoma after conventional chemotherapy: report of a case and review of the literature. Pediatr Hematol Oncol 24(8):615\u2013621. https:\/\/doi.org\/10.1080\/08880010701640390","journal-title":"Pediatr Hematol Oncol"},{"issue":"2","key":"3950_CR7","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1002\/pbc.22841","volume":"57","author":"S Cesaro","year":"2011","unstructured":"Cesaro S, Spiller M, Sartori MT et al (2011) Veno-occlusive disease in pediatric patients affected by Wilms tumor. Pediatr Blood Cancer 57(2):258\u2013261. https:\/\/doi.org\/10.1002\/pbc.22841","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"3950_CR8","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.annonc.2020.02.004","volume":"31","author":"E Charvet","year":"2020","unstructured":"Charvet E, Lheure C, Isnard C et al (2020) Hepatic sinusoidal obstruction syndrome induced by nivolumab in advanced melanoma: a case report. Ann Oncol 31(5):661\u2013662. https:\/\/doi.org\/10.1016\/j.annonc.2020.02.004","journal-title":"Ann Oncol"},{"issue":"1","key":"3950_CR9","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1038\/bmt.2009.153","volume":"45","author":"P Chevallier","year":"2010","unstructured":"Chevallier P, Prebet T, Turlure P et al (2010) Prior treatment with gemtuzumab ozogamicin and the risk of veno-occlusive disease after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transpl 45(1):165\u2013170. https:\/\/doi.org\/10.1038\/bmt.2009.153","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"3950_CR10","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.4143\/crt.2016.096","volume":"48","author":"A Choi","year":"2016","unstructured":"Choi A, Kang YK, Lim S et al (2016) Severe hepatic sinusoidal obstruction syndrome in a child receiving vincristine, actinomycin-D, and cyclophosphamide for rhabdomyosarcoma: successful treatment with defibrotide. Cancer Res Treat 48(4):1443\u20131447. https:\/\/doi.org\/10.4143\/crt.2016.096","journal-title":"Cancer Res Treat"},{"issue":"3","key":"3950_CR11","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/s0168-8278(03)00231-9","volume":"39","author":"M Chojkier","year":"2003","unstructured":"Chojkier M (2003) Hepatic sinusoidal-obstruction syndrome: toxicity of pyrrolizidine alkaloids. J Hepatol 39(3):437\u2013446. https:\/\/doi.org\/10.1016\/s0168-8278(03)00231-9","journal-title":"J Hepatol"},{"issue":"2","key":"3950_CR12","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/bmt.2017.161","volume":"53","author":"S Corbacioglu","year":"2018","unstructured":"Corbacioglu S, Carreras E, Ansari M et al (2018) Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in pediatric patients: a new classification from the European society for blood and marrow transplantation. Bone Marrow Transpl 53(2):138\u2013145. https:\/\/doi.org\/10.1038\/bmt.2017.161","journal-title":"Bone Marrow Transpl"},{"issue":"7","key":"3950_CR13","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1016\/j.bbmt.2019.02.018","volume":"25","author":"S Corbacioglu","year":"2019","unstructured":"Corbacioglu S, Jabbour EJ, Mohty M (2019) Risk factors for development of and progression of hepatic veno-occlusive disease\/sinusoidal obstruction syndrome. Biol Blood Marrow Transpl 25(7):1271\u20131280. https:\/\/doi.org\/10.1016\/j.bbmt.2019.02.018","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"3950_CR14","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/j.1445-5994.1987.tb00089.x","volume":"17","author":"PS Craft","year":"1987","unstructured":"Craft PS, Pembrey RG (1987) Veno-occlusive disease of the liver following chemotherapy with mitomycin C and doxorubicin. Aust N Z J Med 17(4):449\u2013451. https:\/\/doi.org\/10.1111\/j.1445-5994.1987.tb00089.x","journal-title":"Aust N Z J Med"},{"issue":"3","key":"3950_CR15","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.bbmt.2015.09.024","volume":"22","author":"JH Dalle","year":"2016","unstructured":"Dalle JH, Giralt SA (2016) Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment. Biol Blood Marrow Transpl 22(3):400\u2013409. https:\/\/doi.org\/10.1016\/j.bbmt.2015.09.024","journal-title":"Biol Blood Marrow Transpl"},{"issue":"9","key":"3950_CR16","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/s0959-8049(01)00097-1","volume":"37","author":"L D\u2019Antiga","year":"2001","unstructured":"D\u2019Antiga L, Baker A, Pritchard J, Pryor D, Mieli-Vergani G (2001) Veno-occlusive disease with multi-organ involvement following actinomycin-D. Eur J Cancer 37(9):1141\u20131148. https:\/\/doi.org\/10.1016\/s0959-8049(01)00097-1","journal-title":"Eur J Cancer"},{"issue":"4","key":"3950_CR17","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.clinre.2020.03.019","volume":"44","author":"V de Ledinghen","year":"2020","unstructured":"de Ledinghen V, Villate A, Robin M et al (2020) Sinusoidal obstruction syndrome. Clin Res Hepatol Gastroenterol 44(4):480\u2013485. https:\/\/doi.org\/10.1016\/j.clinre.2020.03.019","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"15","key":"3950_CR18","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1182\/bloodadvances.2016001925","volume":"1","author":"DJ DeAngelo","year":"2017","unstructured":"DeAngelo DJ, Stock W, Stein AS et al (2017) Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1\/2 study. Blood Adv 1(15):1167\u20131180. https:\/\/doi.org\/10.1182\/bloodadvances.2016001925","journal-title":"Blood Adv"},{"issue":"4","key":"3950_CR19","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/hep.510240414","volume":"24","author":"LD DeLeve","year":"1996","unstructured":"DeLeve LD (1996) Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology 24(4):830\u2013837. https:\/\/doi.org\/10.1002\/hep.510240414","journal-title":"Hepatology"},{"issue":"4","key":"3950_CR20","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1111\/bjh.12558","volume":"163","author":"FL Dignan","year":"2013","unstructured":"Dignan FL, Wynn RF, Hadzic N et al (2013) BCSH\/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br J Haematol 163(4):444\u2013457. https:\/\/doi.org\/10.1111\/bjh.12558","journal-title":"Br J Haematol"},{"issue":"2","key":"3950_CR21","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1016\/j.clcc.2021.10.003","volume":"21","author":"A Druet","year":"2022","unstructured":"Druet A, Mosnier J, Corbineau E et al (2022) Defibrotide for sinusoidal obstruction syndrome and nodular regenerative hyperplasia after oxaliplatin-based hepatic intra-arterial chemotherapy: a case report. Clin Colorectal Cancer 21(2):e98\u2013e101. https:\/\/doi.org\/10.1016\/j.clcc.2021.10.003","journal-title":"Clin Colorectal Cancer"},{"issue":"32","key":"3950_CR22","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000034698","volume":"102","author":"X Du","year":"2023","unstructured":"Du X, Liu Z, Yu H et al (2023) Prognostic risk factors for patients with hepatic sinusoidal obstruction syndrome caused by pyrrolizidine alkaloids. Med (Baltim) 102(32):e34698. https:\/\/doi.org\/10.1097\/MD.0000000000034698","journal-title":"Med (Baltim)"},{"issue":"8","key":"3950_CR23","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29067","volume":"68","author":"C Duncan","year":"2021","unstructured":"Duncan C, St MA, Perez WS et al (2021) Veno-occlusive disease risk in pediatric patients with acute myeloid leukemia treated with gemtuzumab ozogamicin before allogeneic hematopoietic cell transplantation. Pediatr Blood Cancer 68(8):e29067. https:\/\/doi.org\/10.1002\/pbc.29067","journal-title":"Pediatr Blood Cancer"},{"key":"3950_CR24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.fct.2018.03.005","volume":"115","author":"B Dusemund","year":"2018","unstructured":"Dusemund B, Nowak N, Sommerfeld C, Lindtner O, Sch\u00e4fer B, Lampen A (2018) Risk assessment of pyrrolizidine alkaloids in food of plant and animal origin. Food Chem Toxicol 115:63\u201372. https:\/\/doi.org\/10.1016\/j.fct.2018.03.005","journal-title":"Food Chem Toxicol"},{"issue":"6","key":"3950_CR25","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1016\/j.jhep.2019.02.014","volume":"70","author":"EASL; European Association for the Study of the Liver","year":"2019","unstructured":"EASL; European Association for the Study of the Liver (2019) EASL clinical practice guidelines: drug-induced liver injury. J Hepatol 70(6):1222\u20131261. https:\/\/doi.org\/10.1016\/j.jhep.2019.02.014","journal-title":"J Hepatol"},{"issue":"3","key":"3950_CR26","doi-asserted-by":"publisher","first-page":"209","DOI":"10.4274\/tjh.2014.0214","volume":"33","author":"O Esbah","year":"2016","unstructured":"Esbah O, Tekg\u00fcnd\u00fcz E, \u015eirino\u011flu Demiriz I et al (2016) Finding the optimal conditioning regimen for relapsed\/refractory lymphoma patients undergoing autologous hematopoietic cell transplantation: a retrospective comparison of BEAM and high-dose ICE. Turk J Haematol 33(3):209\u2013215. https:\/\/doi.org\/10.4274\/tjh.2014.0214","journal-title":"Turk J Haematol"},{"issue":"2","key":"3950_CR27","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.dld.2016.10.011","volume":"49","author":"S Fagiuoli","year":"2017","unstructured":"Fagiuoli S, Bruno R, Debernardi Venon W et al (2017) Consensus conference on TIPS management: techniques, indications, contraindications. Dig Liver Dis 49(2):121\u2013137. https:\/\/doi.org\/10.1016\/j.dld.2016.10.011","journal-title":"Dig Liver Dis"},{"issue":"4","key":"3950_CR28","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jceh.2014.10.002","volume":"4","author":"CQ Fan","year":"2014","unstructured":"Fan CQ, Crawford JM (2014) Sinusoidal obstruction syndrome (hepatic veno-occlusive disease). J Clin Exp Hepatol 4(4):332\u2013346. https:\/\/doi.org\/10.1016\/j.jceh.2014.10.002","journal-title":"J Clin Exp Hepatol"},{"issue":"5","key":"3950_CR29","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1093\/annonc\/mdq573","volume":"22","author":"S Ferrari","year":"2011","unstructured":"Ferrari S, Sundby HK, Luksch R et al (2011) Nonmetastatic Ewing family tumors: high-dose chemotherapy with stem cell rescue in poor responder patients. Results of the Italian sarcoma group\/Scandinavian sarcoma group III protocol. Ann Oncol 22(5):1221\u20131227. https:\/\/doi.org\/10.1093\/annonc\/mdq573","journal-title":"Ann Oncol"},{"key":"3950_CR30","doi-asserted-by":"publisher","first-page":"4861","DOI":"10.2147\/DDDT.S87858","volume":"9","author":"H Gao","year":"2015","unstructured":"Gao H, Ruan JQ, Chen J et al (2015) Blood pyrrole-protein adducts as a diagnostic and prognostic index in pyrrolizidine alkaloid-hepatic sinusoidal obstruction syndrome. Drug des Dev Ther 9:4861\u20134868. https:\/\/doi.org\/10.2147\/DDDT.S87858","journal-title":"Drug des Dev Ther"},{"issue":"6","key":"3950_CR31","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1111\/ejh.13618","volume":"106","author":"VM Gonzalez","year":"2021","unstructured":"Gonzalez VM, Diaz DHC, Gonzalez DPJ et al (2021) Defibrotide in hematopoietic stem cell transplantation: a multicenter survey study of the Spanish hematopoietic stem cell transplantation group (GETH). Eur J Haematol 106(6):842\u2013850. https:\/\/doi.org\/10.1111\/ejh.13618","journal-title":"Eur J Haematol"},{"issue":"5","key":"3950_CR32","doi-asserted-by":"publisher","first-page":"e333","DOI":"10.1016\/S2352-3026(23)00011-X","volume":"10","author":"SA Grupp","year":"2023","unstructured":"Grupp SA, Corbacioglu S, Kang HJ et al (2023) Defibrotide plus best standard of care compared with best standard of care alone for the prevention of sinusoidal obstruction syndrome (HARMONY): a randomised, multicentre, phase 3 trial. Lancet Haematol 10(5):e333\u2013e345. https:\/\/doi.org\/10.1016\/S2352-3026(23)00011-X","journal-title":"Lancet Haematol"},{"issue":"1","key":"3950_CR33","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1038\/s41598-018-37775-1","volume":"9","author":"T Guo","year":"2019","unstructured":"Guo T, Li X, Yang X et al (2019) Gadoxetic acid-enhanced hepatobiliary-phase magnetic resonance imaging for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome and association with liver function. Sci Rep 9(1):1231. https:\/\/doi.org\/10.1038\/s41598-018-37775-1","journal-title":"Sci Rep"},{"issue":"2","key":"3950_CR34","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1007\/s12029-022-00835-x","volume":"54","author":"V Gupta","year":"2023","unstructured":"Gupta V, Chopde A, Patkar S, Deodhar K, Goel M (2023) Oxaliplatin-induced sinusoidal obstruction syndrome masquerading as colorectal liver metastasis: a case report. J Gastrointest Cancer 54(2):682\u2013686. https:\/\/doi.org\/10.1007\/s12029-022-00835-x","journal-title":"J Gastrointest Cancer"},{"issue":"2","key":"3950_CR35","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1148\/radiol.13131810","volume":"271","author":"NY Han","year":"2014","unstructured":"Han NY, Park BJ, Sung DJ et al (2014) Chemotherapy-induced focal hepatopathy in patients with gastrointestinal malignancy: gadoxetic acid\u2013enhanced and diffusion-weighted MR imaging with clinical-pathologic correlation. Radiology 271(2):416\u2013425. https:\/\/doi.org\/10.1148\/radiol.13131810","journal-title":"Radiology"},{"issue":"3","key":"3950_CR36","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1148\/radiol.2015141749","volume":"276","author":"NY Han","year":"2015","unstructured":"Han NY, Park BJ, Kim MJ, Sung DJ, Cho SB (2015) Hepatic parenchymal heterogeneity on contrast-enhanced CT scans following oxaliplatin-based chemotherapy: natural history and association with clinical evidence of sinusoidal obstruction syndrome. Radiology 276(3):766\u2013774. https:\/\/doi.org\/10.1148\/radiol.2015141749","journal-title":"Radiology"},{"issue":"3","key":"3950_CR37","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1053\/j.gastro.2024.01.046","volume":"167","author":"Q Herms","year":"2024","unstructured":"Herms Q, Fuster-Anglada C, Juanola A (2024) Pembrolizumab-induced liver injury: beyond immune-mediated hepatitis. Gastroenterology 167(3):443\u2013445. https:\/\/doi.org\/10.1053\/j.gastro.2024.01.046","journal-title":"Gastroenterology"},{"issue":"8","key":"3950_CR38","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.21873\/anticanres.13632","volume":"39","author":"T Hisaka","year":"2019","unstructured":"Hisaka T, Ishikawa H, Sakai H et al (2019) Sinusoidal obstruction syndrome and postoperative complications resulting from preoperative chemotherapy for colorectal cancer liver metastasis. Anticancer Res 39(8):4549\u20134554. https:\/\/doi.org\/10.21873\/anticanres.13632","journal-title":"Anticancer Res"},{"issue":"3","key":"3950_CR39","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1056\/NEJMra1816149","volume":"381","author":"JH Hoofnagle","year":"2019","unstructured":"Hoofnagle JH, Bj\u00f6rnsson ES (2019) Drug-induced liver injury\u2014types and phenotypes. N Engl J Med 381(3):264\u2013273. https:\/\/doi.org\/10.1056\/NEJMra1816149","journal-title":"N Engl J Med"},{"issue":"6","key":"3950_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100719","volume":"5","author":"L Hountondji","year":"2023","unstructured":"Hountondji L, Ferreira DMC, Lebosse F et al (2023) Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort. JHEP Rep 5(6):100719. https:\/\/doi.org\/10.1016\/j.jhepr.2023.100719","journal-title":"JHEP Rep"},{"key":"3950_CR121","doi-asserted-by":"publisher","unstructured":"Hirata M, Tajima H, Miyashita T, et al (2017) Extravasated platelet aggregation in the livers of rats with drug-induced hepatic sinusoidal obstruction syndrome. Mol Med Rep 15(5):3147\u20133152. https:\/\/doi.org\/10.3892\/mmr.2017.6407","DOI":"10.3892\/mmr.2017.6407"},{"issue":"5","key":"3950_CR41","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1016\/j.ejso.2013.12.009","volume":"40","author":"K Imai","year":"2014","unstructured":"Imai K, Emi Y, Iyama KI et al (2014) Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome. Eur J Surg Oncol 40(5):559\u2013566. https:\/\/doi.org\/10.1016\/j.ejso.2013.12.009","journal-title":"Eur J Surg Oncol"},{"issue":"36","key":"3950_CR42","doi-asserted-by":"publisher","first-page":"13408","DOI":"10.12998\/wjcc.v10.i36.13408","volume":"10","author":"JY Jiang","year":"2022","unstructured":"Jiang JY, Fu Y, Ou YJ, Zhang LD (2022) Hepatic sinusoidal obstruction syndrome induced by tacrolimus following liver transplantation: three case reports. World J Clin Cases 10(36):13408\u201313417. https:\/\/doi.org\/10.12998\/wjcc.v10.i36.13408","journal-title":"World J Clin Cases"},{"key":"3950_CR43","doi-asserted-by":"publisher","first-page":"37998","DOI":"10.1038\/srep37998","volume":"6","author":"X Kan","year":"2016","unstructured":"Kan X, Ye J, Rong X et al (2016) Diagnostic performance of contrast-enhanced CT in pyrrolizidine alkaloids-induced hepatic sinusoidal obstructive syndrome. Sci Rep 6:37998. https:\/\/doi.org\/10.1038\/srep37998","journal-title":"Sci Rep"},{"issue":"8","key":"3950_CR44","doi-asserted-by":"publisher","first-page":"e387","DOI":"10.1016\/S2352-3026(17)30103-5","volume":"4","author":"HM Kantarjian","year":"2017","unstructured":"Kantarjian HM, DeAngelo DJ, Advani AS et al (2017) Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol 4(8):e387\u2013e398. https:\/\/doi.org\/10.1016\/S2352-3026(17)30103-5","journal-title":"Lancet Haematol"},{"issue":"14","key":"3950_CR45","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1002\/cncr.32116","volume":"125","author":"HM Kantarjian","year":"2019","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M et al (2019) Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer 125(14):2474\u20132487. https:\/\/doi.org\/10.1002\/cncr.32116","journal-title":"Cancer"},{"issue":"4","key":"3950_CR46","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/s41409-017-0019-y","volume":"53","author":"P Kebriaei","year":"2018","unstructured":"Kebriaei P, Cutler C, de Lima M et al (2018) Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transpl 53(4):449\u2013456. https:\/\/doi.org\/10.1038\/s41409-017-0019-y","journal-title":"Bone Marrow Transpl"},{"key":"3950_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.27269","volume":"65","author":"NA Kernan","year":"2018","unstructured":"Kernan NA, Richardson PG, Smith AR et al (2018a) Defibrotide for the treatment of hepatic veno-occlusive disease\/sinsuoidal obstruction syndrome following nontransplantassociated chemotherapy: final results from a post hoc analysis of data from an expanded-access program. Pediatr Blood Cancer 65:e27269. https:\/\/doi.org\/10.1002\/pbc.27269","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"3950_CR48","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1111\/bjh.15267","volume":"181","author":"NA Kernan","year":"2018","unstructured":"Kernan NA, Grupp S, Smith AR et al (2018b) Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease\/sinusoidal obstruction syndrome. Br J Haematol 181(6):816\u2013827. https:\/\/doi.org\/10.1111\/bjh.15267","journal-title":"Br J Haematol"},{"issue":"2","key":"3950_CR49","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3892\/mco.2019.1864","volume":"11","author":"T Kobayashi","year":"2019","unstructured":"Kobayashi T, Noguchi M, Nakayama H, Fukano R, Ohga S (2019) Adjuvant recombinant thrombomodulin therapy for hepatopathy induced by vincristine, actinomycin D, and cyclophosphamide in pediatric rhabdomyosarcoma: a case report. Mol Clin Oncol 11(2):208\u2013212. https:\/\/doi.org\/10.3892\/mco.2019.1864","journal-title":"Mol Clin Oncol"},{"issue":"5","key":"3950_CR50","doi-asserted-by":"publisher","first-page":"320","DOI":"10.3390\/toxins12050320","volume":"12","author":"T Kopp","year":"2020","unstructured":"Kopp T, Abdel-Tawab M, Mizaikoff B (2020) Extracting and analyzing pyrrolizidine alkaloids in medicinal plants: a review. Toxins (Basel) 12(5):320. https:\/\/doi.org\/10.3390\/toxins12050320","journal-title":"Toxins (Basel)"},{"issue":"2","key":"3950_CR51","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/10428194.2020.1827247","volume":"62","author":"A Ladha","year":"2021","unstructured":"Ladha A, Mannis G, Muffly L (2021) Hepatic veno-occlusive disease in allogeneic stem cell transplant recipients with prior exposure to gemtuzumab ozogamicin or inotuzumab ozogamicin. Leuk Lymphoma 62(2):257\u2013263. https:\/\/doi.org\/10.1080\/10428194.2020.1827247","journal-title":"Leuk Lymphoma"},{"issue":"9","key":"3950_CR52","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1002\/1097-0142(19820501)49:9<1789::aid-cncr2820490910>3.0.co;2-h","volume":"49","author":"HM Lazarus","year":"1982","unstructured":"Lazarus HM, Gottfried MR, Herzig RH et al (1982) Veno-occlusive disease of the liver after high-dose mitomycin C therapy and autologous bone marrow transplantation. Cancer 49(9):1789\u20131795. https:\/\/doi.org\/10.1002\/1097-0142(19820501)49:9%3c1789::aid-cncr2820490910%3e3.0.co;2-h","journal-title":"Cancer"},{"issue":"3","key":"3950_CR53","doi-asserted-by":"publisher","first-page":"123","DOI":"10.5045\/br.2015.50.3.123","volume":"50","author":"JH Lee","year":"2015","unstructured":"Lee JH (2015) Biomarkers for hepatic sinusoidal obstruction syndrome after hematopoietic cell transplantation. Blood Res 50(3):123\u2013125. https:\/\/doi.org\/10.5045\/br.2015.50.3.123","journal-title":"Blood Res"},{"issue":"3","key":"3950_CR54","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1007\/s11060-014-1576-1","volume":"120","author":"SH Lee","year":"2014","unstructured":"Lee SH, Son MH, Sung KW et al (2014) Toxicity of tandem high-dose chemotherapy and autologous stem cell transplantation using carboplatin-thiotepa-etoposide and cyclophosphamide-melphalan regimens for malignant brain tumors in children and young adults. J Neurooncol 120(3):507\u2013513. https:\/\/doi.org\/10.1007\/s11060-014-1576-1","journal-title":"J Neurooncol"},{"issue":"3","key":"3950_CR55","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.hbpd.2020.03.014","volume":"19","author":"L Li","year":"2020","unstructured":"Li L, Dong Y, Li R et al (2020) Sinusoidal obstruction syndrome related to tacrolimus following liver transplantation. Hepatobiliary Pancreat Dis Int 19(3):299\u2013302. https:\/\/doi.org\/10.1016\/j.hbpd.2020.03.014","journal-title":"Hepatobiliary Pancreat Dis Int"},{"issue":"3","key":"3950_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.08.049","volume":"20","author":"C Li","year":"2022","unstructured":"Li C, Ma H, Sun C (2022) Hepatic sinusoidal obstruction syndrome post-liver transplantation: a rare complication of tacrolimus. Clin Gastroenterol Hepatol 20(3):e347. https:\/\/doi.org\/10.1016\/j.cgh.2020.08.049","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"3950_CR57","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1007\/s00270-023-03451-9","volume":"46","author":"S Li","year":"2023","unstructured":"Li S, Li Y, Zhou C et al (2023) Transjugular intrahepatic portosystemic shunt benefits for hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum: a propensity score-matched analysis. Cardiovasc Intervent Radiol 46(7):931\u2013942. https:\/\/doi.org\/10.1007\/s00270-023-03451-9","journal-title":"Cardiovasc Intervent Radiol"},{"issue":"7","key":"3950_CR58","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.dld.2023.12.008","volume":"56","author":"R Li","year":"2024","unstructured":"Li R, Li L, Cai Z et al (2024) Histological evaluation of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome: correlation with Drum Tower Severity Scoring. Dig Liver Dis 56(7):1220\u20131228. https:\/\/doi.org\/10.1016\/j.dld.2023.12.008","journal-title":"Dig Liver Dis"},{"issue":"3","key":"3950_CR59","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3892\/mco.2017.1540","volume":"8","author":"F Liu","year":"2018","unstructured":"Liu F, Cao X, Ye J et al (2018) Oxaliplatin-induced hepatic sinusoidal obstruction syndrome in a patient with gastric cancer: a case report. Mol Clin Oncol 8(3):453\u2013456. https:\/\/doi.org\/10.3892\/mco.2017.1540","journal-title":"Mol Clin Oncol"},{"issue":"1","key":"3950_CR60","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12876-020-1180-0","volume":"20","author":"F Liu","year":"2020","unstructured":"Liu F, Rong X, Guo H et al (2020) Clinical characteristics, CT signs, and pathological findings of pyrrolizidine alkaloids-induced sinusoidal obstructive syndrome: a retrospective study. BMC Gastroenterol 20(1):30. https:\/\/doi.org\/10.1186\/s12876-020-1180-0","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"3950_CR61","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1186\/s12876-022-02523-3","volume":"22","author":"Z Liu","year":"2022","unstructured":"Liu Z, Liang S, Wei X, Du X, Zhang J (2022) Defibrotide improved the outcome of monocrotaline induced rat hepatic sinusoidal obstruction syndrome. BMC Gastroenterol 22(1):525. https:\/\/doi.org\/10.1186\/s12876-022-02523-3","journal-title":"BMC Gastroenterol"},{"issue":"6","key":"3950_CR62","doi-asserted-by":"publisher","first-page":"2398","DOI":"10.3892\/ijmm.2019.4154","volume":"43","author":"Y Lu","year":"2019","unstructured":"Lu Y, Lin Y, Huang X et al (2019) Oxaliplatin aggravates hepatic oxidative stress, inflammation and fibrosis in a non-alcoholic fatty liver disease mouse model. Int J Mol Med 43(6):2398\u20132408. https:\/\/doi.org\/10.3892\/ijmm.2019.4154","journal-title":"Int J Mol Med"},{"issue":"11","key":"3950_CR63","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1093\/annonc\/mds117","volume":"23","author":"R Luksch","year":"2012","unstructured":"Luksch R, Tienghi A, Hall KS et al (2012) Primary metastatic Ewing\u2019s family tumors: results of the Italian sarcoma group and scandinavian sarcoma group ISG\/SSG IV study including myeloablative chemotherapy and total-lung irradiation. Ann Oncol 23(11):2970\u20132976. https:\/\/doi.org\/10.1093\/annonc\/mds117","journal-title":"Ann Oncol"},{"issue":"6","key":"3950_CR64","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1021\/acs.chemrestox.8b00369","volume":"32","author":"J Ma","year":"2019","unstructured":"Ma J, Ruan J, Chen X et al (2019) Pyrrole-hemoglobin adducts, a more feasible potential biomarker of pyrrolizidine alkaloid exposure. Chem Res Toxicol 32(6):1027\u20131039. https:\/\/doi.org\/10.1021\/acs.chemrestox.8b00369","journal-title":"Chem Res Toxicol"},{"issue":"2","key":"3950_CR65","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s12328-019-01042-1","volume":"13","author":"\u00c1 March\u00e1n-L\u00f3pez","year":"2020","unstructured":"March\u00e1n-L\u00f3pez \u00c1, P\u00e9rez-Jacoiste As\u00edn MA, Jim\u00e9nez-Almonacid J, Arroyo-L\u00f3pez M, Justo-Quintas J (2020) Hepatic sinusoidal obstruction syndrome secondary to intravesical instillation of mitomycin-C. Clin J Gastroenterol 13(2):271\u2013275. https:\/\/doi.org\/10.1007\/s12328-019-01042-1","journal-title":"Clin J Gastroenterol"},{"issue":"1","key":"3950_CR66","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3109\/08880018.2012.745178","volume":"30","author":"JF Martin-Lazaro","year":"2013","unstructured":"Martin-Lazaro JF, Palanca D, Garcia-Iniguez JP, Madurga P, Carbone A (2013) Hepatopathy-thrombocytopenia syndrome after actinomycin-D therapy: treatment with defibrotide. Pediatr Hematol Oncol 30(1):25\u201327. https:\/\/doi.org\/10.3109\/08880018.2012.745178","journal-title":"Pediatr Hematol Oncol"},{"issue":"6","key":"3950_CR67","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1007\/s00280-017-3453-z","volume":"80","author":"CL McAtee","year":"2017","unstructured":"McAtee CL, Schneller N, Brackett J, Bernhardt MB, Schafer ES (2017) Treatment-related sinusoidal obstruction syndrome in children with de novo acute lymphoblastic leukemia during intensification. Cancer Chemother Pharmacol 80(6):1261\u20131264. https:\/\/doi.org\/10.1007\/s00280-017-3453-z","journal-title":"Cancer Chemother Pharmacol"},{"issue":"79","key":"3950_CR68","doi-asserted-by":"publisher","first-page":"34857","DOI":"10.18632\/ONCOTARGET.26207","volume":"9","author":"JD Mizrahi","year":"2018","unstructured":"Mizrahi JD, Overman MJ (2018) Bevacizumab as a chemoprotectant: reducing oxaliplatin induced hepatic sinusoidal injury. Oncotarget 9(79):34857\u201334858. https:\/\/doi.org\/10.18632\/ONCOTARGET.26207","journal-title":"Oncotarget"},{"issue":"7","key":"3950_CR69","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1038\/bmt.2016.130","volume":"51","author":"M Mohty","year":"2016","unstructured":"Mohty M, Malard F, Abecassis M et al (2016) Revised diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a new classification from the European society for blood and marrow transplantation. Bone Marrow Transpl 51(7):906\u2013912. https:\/\/doi.org\/10.1038\/bmt.2016.130","journal-title":"Bone Marrow Transpl"},{"issue":"4","key":"3950_CR70","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1038\/s41409-022-01900-6","volume":"58","author":"M Mohty","year":"2023","unstructured":"Mohty M, Blaise D, Peffault de Latour R et al (2023a) Real-world use of defibrotide for veno-occlusive disease\/sinusoidal obstruction syndrome: the DEFIFrance registry study. Bone Marrow Transpl 58(4):367\u2013376. https:\/\/doi.org\/10.1038\/s41409-022-01900-6","journal-title":"Bone Marrow Transpl"},{"issue":"7","key":"3950_CR71","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41409-023-01992-8","volume":"58","author":"M Mohty","year":"2023","unstructured":"Mohty M, Malard F, Alaskar AS et al (2023b) Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a refined classification from the European society for blood and marrow transplantation (EBMT). Bone Marrow Transpl 58(7):749\u2013754. https:\/\/doi.org\/10.1038\/s41409-023-01992-8","journal-title":"Bone Marrow Transpl"},{"issue":"24","key":"3950_CR72","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1200\/JCO.2006.05.7059","volume":"24","author":"O Oberlin","year":"2006","unstructured":"Oberlin O, Rey A, Desfachelles AS et al (2006) Impact of high-dose busulfan plus melphalan as consolidation in metastatic Ewing tumors: a study by the Societe Francaise des Cancers de l\u2019Enfant. J Clin Oncol 24(24):3997\u20134002. https:\/\/doi.org\/10.1200\/JCO.2006.05.7059","journal-title":"J Clin Oncol"},{"issue":"15","key":"3950_CR73","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1200\/JCO.2009.27.5701","volume":"28","author":"MJ Overman","year":"2010","unstructured":"Overman MJ, Maru DM, Charnsangavej C et al (2010) Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol 28(15):2549\u20132555. https:\/\/doi.org\/10.1200\/JCO.2009.27.5701","journal-title":"J Clin Oncol"},{"issue":"2","key":"3950_CR74","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002454","volume":"95","author":"S Park","year":"2016","unstructured":"Park S, Kim HY, Kim H et al (2016) Changes in noninvasive liver fibrosis indices and spleen size during chemotherapy. Medicine 95(2):e2454. https:\/\/doi.org\/10.1097\/MD.0000000000002454","journal-title":"Medicine"},{"issue":"4","key":"3950_CR75","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1002\/hep.30984","volume":"71","author":"E Poli","year":"2020","unstructured":"Poli E, Kounis I, Guettier C et al (2020) Post-liver transplantation sinusoidal obstruction syndrome with refractory ascites induced by mycophenolate mofetil. Hepatology 71(4):1508\u20131510. https:\/\/doi.org\/10.1002\/hep.30984","journal-title":"Hepatology"},{"issue":"1","key":"3950_CR76","doi-asserted-by":"publisher","first-page":"171","DOI":"10.15403\/jgld-3207","volume":"30","author":"M Riveiro-Barciela","year":"2021","unstructured":"Riveiro-Barciela M, Gonzalez-Sans D, Marmolejo D, Salcedo MT, Munoz-Couselo E (2021) Hepatic sinusoidal obstruction syndrome associated with nivolumab: an uncommon adverse event related to immune checkpoint inhibitors. J Gastrointestin Liver Dis 30(1):171\u2013172. https:\/\/doi.org\/10.15403\/jgld-3207","journal-title":"J Gastrointestin Liver Dis"},{"issue":"4","key":"3950_CR77","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.cld.2010.07.009","volume":"14","author":"L Rubbia-Brandt","year":"2010","unstructured":"Rubbia-Brandt L (2010) Sinusoidal obstruction syndrome. Clin Liver Dis 14(4):651\u2013668. https:\/\/doi.org\/10.1016\/j.cld.2010.07.009","journal-title":"Clin Liver Dis"},{"issue":"3","key":"3950_CR78","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1093\/annonc\/mdh095","volume":"15","author":"L Rubbia-Brandt","year":"2004","unstructured":"Rubbia-Brandt L, Audard V, Sartoretti P et al (2004) Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15(3):460\u2013466. https:\/\/doi.org\/10.1093\/annonc\/mdh095","journal-title":"Ann Oncol"},{"key":"3950_CR79","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ijsu.2016.05.065","volume":"31","author":"N Russolillo","year":"2016","unstructured":"Russolillo N, Langella S, Perotti S et al (2016) Preoperative assessment of chemotherapeutic associated liver injury based on indocyanine green retention test. Int J Surg 31:80\u201385. https:\/\/doi.org\/10.1016\/j.ijsu.2016.05.065","journal-title":"Int J Surg"},{"issue":"7","key":"3950_CR80","doi-asserted-by":"publisher","first-page":"1180","DOI":"10.1007\/s12094-019-02245-1","volume":"22","author":"P Saez-Carlin","year":"2020","unstructured":"Saez-Carlin P, Garc\u00eda-Botella A, Diez-Valladares LI et al (2020) Splenic volume as a biomarker of hepatic damage after chemotherapy in patients with resected colorectal liver metastases (CRLM). Clin Transl Oncol 22(7):1180\u20131186. https:\/\/doi.org\/10.1007\/s12094-019-02245-1","journal-title":"Clin Transl Oncol"},{"issue":"4","key":"3950_CR81","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2169\/internalmedicine.56.7669","volume":"56","author":"M Sakumura","year":"2017","unstructured":"Sakumura M, Tajiri K, Miwa S et al (2017) Hepatic sinusoidal obstruction syndrome induced by non-transplant chemotherapy for non-hodgkin lymphoma. Intern Med 56(4):395\u2013400. https:\/\/doi.org\/10.2169\/internalmedicine.56.7669","journal-title":"Intern Med"},{"key":"3950_CR82","doi-asserted-by":"publisher","DOI":"10.1016\/j.trim.2022.101557","volume":"71","author":"Y Sanada","year":"2022","unstructured":"Sanada Y, Sakuma Y, Onishi Y et al (2022) Prevalence and outcomes of patients with sinusoidal obstruction syndrome after liver transplantation: a ten year\u2019s experience of a single center in Japan. Transpl Immunol 71:101557. https:\/\/doi.org\/10.1016\/j.trim.2022.101557","journal-title":"Transpl Immunol"},{"issue":"4","key":"3950_CR83","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000001038","volume":"10","author":"NY Sarsour","year":"2023","unstructured":"Sarsour NY, Minervini M, Malik SM (2023) Cemiplimab-associated sinusoidal obstruction syndrome. ACG Case Rep J 10(4):e1038. https:\/\/doi.org\/10.14309\/crj.0000000000001038","journal-title":"ACG Case Rep J"},{"issue":"3","key":"3950_CR84","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1038\/s41409-018-0298-y","volume":"55","author":"T Schechter","year":"2020","unstructured":"Schechter T, Perez-Albuerne E, Lin TF et al (2020) Veno-occlusive disease after high-dose busulfan-melphalan in neuroblastoma. Bone Marrow Transpl 55(3):531\u2013537. https:\/\/doi.org\/10.1038\/s41409-018-0298-y","journal-title":"Bone Marrow Transpl"},{"issue":"7","key":"3950_CR85","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1002\/lt.22282","volume":"17","author":"M Sebagh","year":"2011","unstructured":"Sebagh M, Azoulay D, Roche B et al (2011) Significance of isolated hepatic veno-occlusive disease\/sinusoidal obstruction syndrome after liver transplantation. Liver Transpl 17(7):798\u2013808. https:\/\/doi.org\/10.1002\/lt.22282","journal-title":"Liver Transpl"},{"issue":"1","key":"3950_CR86","doi-asserted-by":"publisher","first-page":"11","DOI":"10.21037\/atm-20-731","volume":"9","author":"H Shang","year":"2021","unstructured":"Shang H, Bai T, Zhu S et al (2021) Prognostic factors for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome: a multicenter study in China. Ann Transl Med 9(1):11. https:\/\/doi.org\/10.21037\/atm-20-731","journal-title":"Ann Transl Med"},{"issue":"8","key":"3950_CR87","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1053\/j.gastro.2019.02.002","volume":"156","author":"T Shen","year":"2019","unstructured":"Shen T, Liu Y, Shang J et al (2019) Incidence and etiology of drug-induced liver injury in mainland China. Gastroenterology 156(8):2230\u20132241. https:\/\/doi.org\/10.1053\/j.gastro.2019.02.002","journal-title":"Gastroenterology"},{"issue":"9","key":"3950_CR88","doi-asserted-by":"publisher","first-page":"2650","DOI":"10.1038\/s41375-021-01203-7","volume":"35","author":"M Stanulla","year":"2021","unstructured":"Stanulla M, Schaeffeler E, M\u00f6ricke A et al (2021) Hepatic sinusoidal obstruction syndrome and short-term application of 6-thioguanine in pediatric acute lymphoblastic leukemia. Leukemia 35(9):2650\u20132657. https:\/\/doi.org\/10.1038\/s41375-021-01203-7","journal-title":"Leukemia"},{"issue":"1","key":"3950_CR89","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12885-016-2998-2","volume":"17","author":"HL Stevenson","year":"2017","unstructured":"Stevenson HL, Prats MM, Sasatomi E (2017) Chemotherapy-induced sinusoidal Injury (CSI) score: a novel histologic assessment of chemotherapy-related hepatic sinusoidal injury in patients with colorectal liver metastasis. BMC Cancer 17(1):35. https:\/\/doi.org\/10.1186\/s12885-016-2998-2","journal-title":"BMC Cancer"},{"issue":"14","key":"3950_CR90","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1182\/blood-2009-07-230656","volume":"115","author":"LC Stork","year":"2010","unstructured":"Stork LC, Matloub Y, Broxson E et al (2010) Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the children\u2019s oncology group CCG-1952 clinical trial. Blood 115(14):2740\u20132748. https:\/\/doi.org\/10.1182\/blood-2009-07-230656","journal-title":"Blood"},{"issue":"12","key":"3950_CR91","first-page":"843","volume":"26","author":"ML Sulis","year":"2004","unstructured":"Sulis ML, Bessmertny O, Granowetter L, Weiner M, Kelly KM (2004) Veno-occlusive disease in pediatric patients receiving actinomycin D and vincristine only for the treatment of rhabdomyosarcoma. J Pediatr Hematol Oncol 26(12):843\u2013846","journal-title":"J Pediatr Hematol Oncol"},{"issue":"17","key":"3950_CR120","doi-asserted-by":"publisher","first-page":"e552","DOI":"10.1097\/MD.0000000000010552","volume":"97","author":"Z Sun","year":"2018","unstructured":"Sun Z, Kang J, Zhang Y (2018) Hepatic veno-occlusive disease related to Gynura segetum: A case report. Medicine (Baltimore) 97(17): e552. https:\/\/doi.org\/10.1097\/MD.0000000000010552","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"3950_CR92","doi-asserted-by":"publisher","first-page":"20230737","DOI":"10.1515\/med-2023-0737","volume":"18","author":"Y Tan","year":"2023","unstructured":"Tan Y, Zheng S (2023) Clinicopathological characteristics and diagnosis of hepatic sinusoidal obstruction syndrome caused by Tusanqi - Case report and literature review. Open Med (Wars) 18(1):20230737. https:\/\/doi.org\/10.1515\/med-2023-0737","journal-title":"Open Med (Wars)"},{"issue":"6","key":"3950_CR93","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000035914","volume":"103","author":"Y Tan","year":"2024","unstructured":"Tan Y, Zhou X (2024) Anticoagulant therapy likely increases risk of bleeding in Gynura segetum-induced hepatic sinus obstruction syndrome. Medicine 103(6):e35914. https:\/\/doi.org\/10.1097\/MD.0000000000035914","journal-title":"Medicine"},{"issue":"8","key":"3950_CR94","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.clml.2017.06.032","volume":"17","author":"C Tang","year":"2017","unstructured":"Tang C, Lindsay J, Gill A, Kerridge I (2017) Defibrotide use in vincristine-induced hepatic sinusoidal obstruction syndrome. Clin Lymphoma Myeloma Leuk 17(8):539\u2013541. https:\/\/doi.org\/10.1016\/j.clml.2017.06.032","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"19","key":"3950_CR95","doi-asserted-by":"publisher","first-page":"10419","DOI":"10.3390\/ijms221910419","volume":"22","author":"R Teschke","year":"2021","unstructured":"Teschke R, Vongdala N, Quan NV, Quy TN, Xuan TD (2021) Metabolic toxification of 1,2-unsaturated pyrrolizidine alkaloids causes human hepatic sinusoidal obstruction syndrome: the update. Int J Mol Sci 22(19):10419. https:\/\/doi.org\/10.3390\/ijms221910419","journal-title":"Int J Mol Sci"},{"key":"3950_CR96","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26519","author":"LN Toksvang","year":"2017","unstructured":"Toksvang LN, De Pietri S, Nielsen SN et al (2017) Hepatic sinusoidal obstruction syndrome during maintenance therapy of childhood acute lymphoblastic leukemia is associated with continuous asparaginase therapy and mercaptopurine metabolites. Pediatr Blood Cancer. https:\/\/doi.org\/10.1002\/pbc.26519","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"3950_CR97","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212157","volume":"14","author":"LN Toksvang","year":"2019","unstructured":"Toksvang LN, Schmidt MS, Arup S et al (2019) Hepatotoxicity during 6-thioguanine treatment in inflammatory bowel disease and childhood acute lymphoblastic leukaemia: a systematic review. PLoS ONE 14(5):e212157. https:\/\/doi.org\/10.1371\/journal.pone.0212157","journal-title":"PLoS ONE"},{"issue":"4","key":"3950_CR98","doi-asserted-by":"publisher","first-page":"447","DOI":"10.4103\/ijmpo.ijmpo_188_16","volume":"38","author":"S Totadri","year":"2017","unstructured":"Totadri S, Trehan A, Bansal D, Jain R (2017) Sinusoidal obstruction syndrome during treatment for Wilms\u2019 tumor: a life-threatening complication. Indian J Med Paediatr Oncol 38(4):447\u2013451. https:\/\/doi.org\/10.4103\/ijmpo.ijmpo_188_16","journal-title":"Indian J Med Paediatr Oncol"},{"issue":"4","key":"3950_CR99","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1477-2574.2012.00540.x","volume":"15","author":"J Urdzik","year":"2013","unstructured":"Urdzik J, Bjerner T, Wanders A et al (2013) Magnetic resonance imaging flowmetry demonstrates portal vein dilatation subsequent to oxaliplatin therapy in patients with colorectal liver metastasis. HPB 15(4):265\u2013272. https:\/\/doi.org\/10.1111\/j.1477-2574.2012.00540.x","journal-title":"HPB"},{"issue":"4","key":"3950_CR100","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.clinre.2016.01.006","volume":"40","author":"DC Valla","year":"2016","unstructured":"Valla DC, Cazals-Hatem D (2016) Sinusoidal obstruction syndrome. Clin Res Hepatol Gastroenterol 40(4):378\u2013385. https:\/\/doi.org\/10.1016\/j.clinre.2016.01.006","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"3","key":"3950_CR101","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.suronc.2016.05.030","volume":"25","author":"KM van Mierlo","year":"2016","unstructured":"van Mierlo KM, Zhao J, Kleijnen J et al (2016) The influence of chemotherapy-associated sinusoidal dilatation on short-term outcome after partial hepatectomy for colorectal liver metastases: a systematic review with meta-analysis. Surg Oncol 25(3):298\u2013307. https:\/\/doi.org\/10.1016\/j.suronc.2016.05.030","journal-title":"Surg Oncol"},{"issue":"16","key":"3950_CR102","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1016\/j.ejca.2012.05.020","volume":"48","author":"GJ Veal","year":"2012","unstructured":"Veal GJ, Nguyen L, Paci A et al (2012) Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1\/SIOPEN trial. Eur J Cancer 48(16):3063\u20133072. https:\/\/doi.org\/10.1016\/j.ejca.2012.05.020","journal-title":"Eur J Cancer"},{"issue":"1","key":"3950_CR103","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12876-018-0879-7","volume":"18","author":"Y Wang","year":"2018","unstructured":"Wang Y, Qiao D, Li Y, Xu F (2018) Risk factors for hepatic veno-occlusive disease caused by Gynura segetum: a retrospective study. BMC Gastroenterol 18(1):156. https:\/\/doi.org\/10.1186\/s12876-018-0879-7","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"3950_CR104","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1038\/s41598-019-38669-6","volume":"9","author":"C Wang","year":"2019","unstructured":"Wang C, Wu X, Xie W et al (2019) Quantitative analysis of CT images in patients with pyrrolizidine alkaloid-induced sinusoidal obstruction syndrome. Sci Rep 9(1):2179. https:\/\/doi.org\/10.1038\/s41598-019-38669-6","journal-title":"Sci Rep"},{"key":"3950_CR105","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.627126","volume":"12","author":"X Wang","year":"2021","unstructured":"Wang X, Zhang W, Yang Y et al (2021) Blood microRNA signatures serve as potential diagnostic biomarkers for hepatic sinusoidal obstruction syndrome caused by Gynura japonica containing pyrrolizidine alkaloids. Front Pharmacol 12:627126. https:\/\/doi.org\/10.3389\/fphar.2021.627126","journal-title":"Front Pharmacol"},{"issue":"3","key":"3950_CR106","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1007\/s12072-021-10293-5","volume":"16","author":"X Wang","year":"2022","unstructured":"Wang X, Zhang W, Zhang M et al (2022) Development of a Drum Tower Severity Scoring (DTSS) system for pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome. Hepatol Int 16(3):669\u2013679. https:\/\/doi.org\/10.1007\/s12072-021-10293-5","journal-title":"Hepatol Int"},{"issue":"2","key":"3950_CR107","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.suc.2015.11.005","volume":"96","author":"MA White","year":"2016","unstructured":"White MA, Fong Y, Singh G (2016) Chemotherapy-associated hepatotoxicities. Surg Clin North Am 96(2):207\u2013217. https:\/\/doi.org\/10.1016\/j.suc.2015.11.005","journal-title":"Surg Clin North Am"},{"key":"3950_CR108","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.jhep.2019.02.014","volume":"196","author":"FC Willmot","year":"1920","unstructured":"Willmot FC, Robertson GW (1920) Senecio disease or cirrhosis of the liver due to Senecio poisoning. Lancet 196:848\u2013849. https:\/\/doi.org\/10.1016\/j.jhep.2019.02.014","journal-title":"Lancet"},{"issue":"3","key":"3950_CR109","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/bmt.2015.283","volume":"51","author":"K Yakushijin","year":"2016","unstructured":"Yakushijin K, Atsuta Y, Doki N et al (2016) Sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomes. Bone Marrow Transpl 51(3):403\u2013409. https:\/\/doi.org\/10.1038\/bmt.2015.283","journal-title":"Bone Marrow Transpl"},{"issue":"28","key":"3950_CR110","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.3748\/wjg.v25.i28.3753","volume":"25","author":"XQ Yang","year":"2019","unstructured":"Yang XQ, Ye J, Li X, Li Q, Song YH (2019) Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes. World J Gastroenterol 25(28):3753\u20133763. https:\/\/doi.org\/10.3748\/wjg.v25.i28.3753","journal-title":"World J Gastroenterol"},{"key":"3950_CR111","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ajem.2021.08.038","volume":"50","author":"MJ Yoo","year":"2021","unstructured":"Yoo MJ, Long B, Brady WJ et al (2021) Immune checkpoint inhibitors: an emergency medicine focused review. Am J Emerg Med 50:335\u2013344. https:\/\/doi.org\/10.1016\/j.ajem.2021.08.038","journal-title":"Am J Emerg Med"},{"issue":"8","key":"3950_CR112","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1038\/s41409-019-0492-6","volume":"54","author":"JH Yoon","year":"2019","unstructured":"Yoon JH, Yoo KH, Sung KW et al (2019) Validation of treatment outcomes according to revised severity criteria from European society for blood and marrow transplantation (EBMT) for sinusoidal obstruction syndrome\/veno-occlusive disease (SOS\/VOD). Bone Marrow Transpl 54(8):1361\u20131368. https:\/\/doi.org\/10.1038\/s41409-019-0492-6","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"3950_CR113","doi-asserted-by":"publisher","first-page":"345","DOI":"10.14218\/JCTH.2020.00124","volume":"9","author":"W Zhang","year":"2021","unstructured":"Zhang W, Liu L, Zhang M et al (2021) Validation of the Nanjing criteria for diagnosing pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome. J Clin Transl Hepatol 9(3):345\u2013352. https:\/\/doi.org\/10.14218\/JCTH.2020.00124","journal-title":"J Clin Transl Hepatol"},{"issue":"8","key":"3950_CR114","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1002\/bjs.10572","volume":"104","author":"J Zhao","year":"2017","unstructured":"Zhao J, van Mierlo K, Gomez-Ramirez J et al (2017) Systematic review of the influence of chemotherapy-associated liver injury on outcome after partial hepatectomy for colorectal liver metastases. Br J Surg 104(8):990\u20131002. https:\/\/doi.org\/10.1002\/bjs.10572","journal-title":"Br J Surg"},{"issue":"5","key":"3950_CR115","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1093\/gastro\/goaa056","volume":"9","author":"S Zhou","year":"2021","unstructured":"Zhou S, Feng D, Zhang N et al (2021) Hepatic sinusoidal obstruction syndrome due to tacrolimus in a liver-transplantation recipient. Gastroenterol Rep (Oxf) 9(5):485\u2013487. https:\/\/doi.org\/10.1093\/gastro\/goaa056","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"3950_CR116","doi-asserted-by":"publisher","DOI":"10.1016\/j.tox.2021.152882","volume":"460","author":"C Zhu","year":"2021","unstructured":"Zhu C, Ren X, Liu D, Zhang C (2021a) Oxaliplatin-induced hepatic sinusoidal obstruction syndrome. Toxicology 460:152882. https:\/\/doi.org\/10.1016\/j.tox.2021.152882","journal-title":"Toxicology"},{"issue":"8","key":"3950_CR117","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/s41401-020-00553-9","volume":"42","author":"L Zhu","year":"2021","unstructured":"Zhu L, Zhang CY, Li DP et al (2021b) Tu-San-Qi (Gynura japonica): the culprit behind pyrrolizidine alkaloid-induced liver injury in China. Acta Pharmacol Sin 42(8):1212\u20131222. https:\/\/doi.org\/10.1038\/s41401-020-00553-9","journal-title":"Acta Pharmacol Sin"},{"issue":"10","key":"3950_CR118","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1111\/liv.13684","volume":"38","author":"YZ Zhuge","year":"2018","unstructured":"Zhuge YZ, Wang Y, Zhang F et al (2018) Clinical characteristics and treatment of pyrrolizidine alkaloid-related hepatic vein occlusive disease. Liver Int 38(10):1867\u20131874. https:\/\/doi.org\/10.1111\/liv.13684","journal-title":"Liver Int"},{"issue":"4","key":"3950_CR119","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/jgh.14612","volume":"34","author":"Y Zhuge","year":"2019","unstructured":"Zhuge Y, Liu Y, Xie W et al (2019) Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome. J Gastroenterol Hepatol 34(4):634\u2013642. https:\/\/doi.org\/10.1111\/jgh.14612","journal-title":"J Gastroenterol Hepatol"}],"container-title":["Archives of Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-024-03950-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00204-024-03950-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00204-024-03950-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T02:36:31Z","timestamp":1739327791000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00204-024-03950-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,24]]},"references-count":121,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["3950"],"URL":"https:\/\/doi.org\/10.1007\/s00204-024-03950-9","relation":{},"ISSN":["0340-5761","1432-0738"],"issn-type":[{"value":"0340-5761","type":"print"},{"value":"1432-0738","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,24]]},"assertion":[{"value":"1 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no confict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The manuscript does not contain experimental work, clinical studies, or patient data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All authors declare that they have agreed to publish this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}